Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Navitor Pharmaceuticals is raising $20,186,771.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Thomas Hughes played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Navitor Pharmaceuticals

Navitor Pharmaceuticals, Inc. is the leader in the development of mTORC1-targeted therapeutics designed to help patients live longer and healthier lives. The Company’s proprietary platform enables specific modulation of mTORC1, the gatekeeper of cellular metabolism and renewal, with the first-ever absolutely selective mTORC1 inhibition and the unique ability for mTORC1 activation.  Navitor’s lead clinical-stage candidate, NV-5138, is a small molecule that directly activates mTORC1 by binding to sestrin, a key regulatory component of the mTORC1 complex that recognizes the essential amino acid leucine, and is being developed for treatment-resistant depression, with additional opportunities in cognition and memory.

To learn more about Navitor Pharmaceuticals, visit http://www.navitorpharma.com/

Contact:
Thomas Hughes, Chief Executive Officer
857-285-4300
https://www.linkedin.com/in/tom-hughes-04b514/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved